Moleculin Short Term Debt vs Capital Stock Analysis

MBRX Stock

USD 4.63 0.32 7.42%

Moleculin Biotech financial indicator trend analysis is infinitely more than just investigating Moleculin Biotech recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Moleculin Biotech is a good investment. Please check the relationship between Moleculin Biotech Short Term Debt and its Capital Stock accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

Short Term Debt vs Capital Stock

Short Term Debt vs Capital Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Moleculin Biotech Short Term Debt account and Capital Stock. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Moleculin Biotech's Short Term Debt and Capital Stock is -0.44. Overlapping area represents the amount of variation of Short Term Debt that can explain the historical movement of Capital Stock in the same time period over historical financial statements of Moleculin Biotech, assuming nothing else is changed. The correlation between historical values of Moleculin Biotech's Short Term Debt and Capital Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Debt of Moleculin Biotech are associated (or correlated) with its Capital Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Stock has no effect on the direction of Short Term Debt i.e., Moleculin Biotech's Short Term Debt and Capital Stock go up and down completely randomly.

Correlation Coefficient

-0.44

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Short Term Debt

Capital Stock

The total amount of a company’s capital funded by shareholders through the issue and subscription of shares.

Most indicators from Moleculin Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.Selling General Administrative is likely to drop to 9,516 in 2024. Issuance Of Capital Stock is likely to drop to about 200.4 K in 2024

Moleculin Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Retained Earnings Total Equity	Capital Surpluse
Total Assets		-0.51	0.43	0.73	0.99	0.8	-0.98	-0.75	0.69	0.98	0.98	0.83	-0.75	0.29	0.92	0.56	-0.74	0.98	-0.79	0.55	0.33	0.71	0.57	-0.8	-0.87	0.84
Short Long Term Debt Total	-0.51		-0.04	0.04	-0.54	-0.01	0.5	-0.04	0.09	-0.5	-0.5	-0.2	0.46	-0.13	-0.18	-0.09	0.38	-0.49	0.32	-0.37	-0.34	-0.08	-0.04	0.19	0.3	-0.2
Other Current Liab	0.43	-0.04		0.65	0.37	0.66	-0.36	-0.71	0.21	0.34	0.34	0.67	-0.49	0.39	0.53	0.58	-0.6	0.35	-0.51	0.42	0.23	0.54	0.73	-0.59	-0.53	0.51
Total Current Liabilities	0.73	0.04	0.65		0.65	0.78	-0.63	-0.89	0.81	0.62	0.62	0.87	-0.75	0.53	0.9	0.84	-0.82	0.65	-0.85	0.65	0.41	0.92	0.72	-0.73	-0.85	0.9
Total Stockholder Equity	0.99	-0.54	0.37	0.65		0.78	-0.99	-0.68	0.64	0.99	0.99	0.75	-0.68	0.15	0.88	0.43	-0.67	0.99	-0.71	0.44	0.21	0.6	0.49	-0.74	-0.79	0.76
Net Tangible Assets	0.8	-0.01	0.66	0.78	0.78		-0.79	-0.94	0.71	0.79	0.79	0.86	-0.54	0.22	0.89	0.52	-0.58	0.79	-0.66	0.35	0.14	0.68	0.77	-0.87	-0.77	0.74
Net Debt	-0.98	0.5	-0.36	-0.63	-0.99	-0.79		0.69	-0.62	-1.0	-1.0	-0.75	0.6	-0.17	-0.88	-0.43	0.58	-1.0	0.7	-0.42	-0.21	-0.6	-0.49	0.78	0.8	-0.77
Retained Earnings	-0.75	-0.04	-0.71	-0.89	-0.68	-0.94	0.69		-0.78	-0.68	-0.68	-0.96	0.67	-0.5	-0.9	-0.76	0.7	-0.7	0.79	-0.6	-0.42	-0.86	-0.89	0.91	0.88	-0.86
Accounts Payable	0.69	0.09	0.21	0.81	0.64	0.71	-0.62	-0.78		0.62	0.62	0.75	-0.64	0.3	0.82	0.6	-0.64	0.64	-0.73	0.51	0.33	0.8	0.62	-0.66	-0.78	0.77
Cash	0.98	-0.5	0.34	0.62	0.99	0.79	-1.0	-0.68	0.62		1.0	0.75	-0.59	0.17	0.88	0.42	-0.58	1.0	-0.69	0.41	0.21	0.6	0.47	-0.77	-0.79	0.77
Cash And Short Term Investments	0.98	-0.5	0.34	0.62	0.99	0.79	-1.0	-0.68	0.62	1.0		0.75	-0.59	0.17	0.88	0.42	-0.58	1.0	-0.69	0.41	0.21	0.6	0.47	-0.77	-0.79	0.77
Common Stock Total Equity	0.83	-0.2	0.67	0.87	0.75	0.86	-0.75	-0.96	0.75	0.75	0.75		-0.79	0.64	0.91	0.84	-0.78	0.77	-0.88	0.78	0.62	0.92	0.88	-0.93	-0.97	0.93
Common Stock Shares Outstanding	-0.75	0.46	-0.49	-0.75	-0.68	-0.54	0.6	0.67	-0.64	-0.59	-0.59	-0.79		-0.59	-0.73	-0.77	0.97	-0.61	0.83	-0.8	-0.63	-0.77	-0.63	0.62	0.8	-0.77
Non Current Liabilities Total	0.29	-0.13	0.39	0.53	0.15	0.22	-0.17	-0.5	0.3	0.17	0.17	0.64	-0.59		0.42	0.91	-0.51	0.2	-0.67	0.89	0.92	0.75	0.57	-0.51	-0.66	0.67
Other Stockholder Equity	0.92	-0.18	0.53	0.9	0.88	0.89	-0.88	-0.9	0.82	0.88	0.88	0.91	-0.73	0.42		0.72	-0.75	0.89	-0.84	0.59	0.36	0.85	0.66	-0.88	-0.92	0.94
Total Liab	0.56	-0.09	0.58	0.84	0.43	0.52	-0.43	-0.76	0.6	0.42	0.42	0.84	-0.77	0.91	0.72		-0.75	0.46	-0.86	0.9	0.8	0.94	0.72	-0.69	-0.85	0.88
Short Long Term Debt	-0.74	0.38	-0.6	-0.82	-0.67	-0.58	0.58	0.7	-0.64	-0.58	-0.58	-0.78	0.97	-0.51	-0.75	-0.75		-0.6	0.8	-0.74	-0.51	-0.76	-0.63	0.6	0.77	-0.76
Total Current Assets	0.98	-0.49	0.35	0.65	0.99	0.79	-1.0	-0.7	0.64	1.0	1.0	0.77	-0.61	0.2	0.89	0.46	-0.6		-0.72	0.44	0.24	0.63	0.5	-0.78	-0.81	0.79
Short Term Debt	-0.79	0.32	-0.51	-0.85	-0.71	-0.66	0.7	0.79	-0.73	-0.69	-0.69	-0.88	0.83	-0.67	-0.84	-0.86	0.8	-0.72		-0.8	-0.67	-0.94	-0.75	0.75	0.92	-0.89
Common Stock	0.55	-0.37	0.42	0.65	0.44	0.35	-0.42	-0.6	0.51	0.41	0.41	0.78	-0.8	0.89	0.59	0.9	-0.74	0.44	-0.8		0.94	0.84	0.67	-0.64	-0.83	0.8
Other Liab	0.33	-0.34	0.23	0.41	0.21	0.14	-0.21	-0.42	0.33	0.21	0.21	0.62	-0.63	0.92	0.36	0.8	-0.51	0.24	-0.67	0.94		0.7	0.58	-0.48	-0.67	0.61
Property Plant And Equipment Net	0.71	-0.08	0.54	0.92	0.6	0.68	-0.6	-0.86	0.8	0.6	0.6	0.92	-0.77	0.75	0.85	0.94	-0.76	0.63	-0.94	0.84	0.7		0.79	-0.79	-0.94	0.94
Non Current Assets Total	0.57	-0.04	0.73	0.72	0.49	0.77	-0.49	-0.89	0.62	0.47	0.47	0.88	-0.63	0.57	0.66	0.72	-0.63	0.5	-0.75	0.67	0.58	0.79		-0.77	-0.8	0.68
Non Currrent Assets Other	-0.8	0.19	-0.59	-0.73	-0.74	-0.87	0.78	0.91	-0.66	-0.77	-0.77	-0.93	0.62	-0.51	-0.88	-0.69	0.6	-0.78	0.75	-0.64	-0.48	-0.79	-0.77		0.9	-0.87
Retained Earnings Total Equity	-0.87	0.3	-0.53	-0.85	-0.79	-0.77	0.8	0.88	-0.78	-0.79	-0.79	-0.97	0.8	-0.66	-0.92	-0.85	0.77	-0.81	0.92	-0.83	-0.67	-0.94	-0.8	0.9		-0.97
Capital Surpluse	0.84	-0.2	0.51	0.9	0.76	0.74	-0.77	-0.86	0.77	0.77	0.77	0.93	-0.77	0.67	0.94	0.88	-0.76	0.79	-0.89	0.8	0.61	0.94	0.68	-0.87	-0.97

Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	25.2M	29.0M	84.1M	57.4M	38.2M	35.4M
Other Current Liab	164K	1.7M	2.2M	(116K)	4.2M	4.4M
Total Current Liabilities	3.6M	2.9M	3.6M	4.8M	6.8M	3.7M
Total Stockholder Equity	15.6M	17.8M	79.0M	52.2M	26.1M	28.9M
Net Tangible Assets	3.1M	4.4M	6.6M	67.8M	78.0M	81.9M
Net Debt	(10.4M)	(14.9M)	(70.7M)	(42.7M)	(23.0M)	(24.1M)
Retained Earnings	(39.6M)	(56.9M)	(72.8M)	(101.8M)	(131.6M)	(125.0M)
Accounts Payable	2.2M	1.1M	1.4M	4.8M	2.5M	1.8M
Cash	10.7M	15.2M	70.9M	43.1M	23.6M	22.4M
Cash And Short Term Investments	10.7M	15.2M	70.9M	43.1M	23.6M	22.4M
Common Stock Total Equity	21K	29K	46K	69K	79.4K	83.3K
Common Stock Shares Outstanding	452.5K	656.4K	1.8M	1.9M	2.0M	2.3M
Liabilities And Stockholders Equity	25.2M	29.0M	84.1M	57.4M	38.2M	35.4M
Non Current Liabilities Total	6.1M	8.4M	1.5M	412K	5.3M	2.9M
Other Stockholder Equity	55.1M	74.5M	151.7M	154.0M	157.7M	83.7M
Total Liab	9.7M	11.3M	5.1M	5.2M	12.1M	6.5M
Total Current Assets	13.5M	17.2M	72.5M	45.6M	26.3M	24.0M
Short Term Debt	103K	118K	96K	116K	100K	174.4K
Common Stock	21K	29K	46K	69K	33K	33.6K
Other Liab	1.4M	5.8M	8.2M	1.4M	1.6M	3.1M
Property Plant And Equipment Net	603K	685K	445K	678K	796K	512.3K
Non Current Assets Total	11.8M	11.8M	11.6M	11.8M	11.9M	12.8M
Retained Earnings Total Equity	(14.5M)	(26.4M)	(39.6M)	(56.9M)	(51.2M)	(48.7M)
Capital Surpluse	31.6M	40.6M	55.1M	74.7M	85.9M	48.7M
Other Current Assets	529K	164K	1.6M	2.5M	2.6M	2.8M
Property Plant And Equipment Gross	603K	685K	1.1M	678K	1.7M	1.8M
Accumulated Other Comprehensive Income	31K	65K	41K	12K	(9K)	(8.6K)
Property Plant Equipment	463K	603K	685K	445K	511.8K	412.9K
Net Invested Capital	15.6M	17.8M	79.0M	52.2M	26.1M	34.9M
Net Working Capital	9.9M	14.3M	68.9M	40.8M	19.5M	25.7M
Net Receivables	11K	1K	45K	22K	99K	104.0K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Moleculin Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moleculin Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moleculin Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moleculin Biotech Stock:

How To Invest In Moleculin

Details

Is Moleculin Stock a good investment?

Details

What is Moleculin Biotech's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.

	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
	Global Correlations Find global opportunities by holding instruments from different markets
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges

Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(15.15)

Return On Assets

(0.39)

Return On Equity

(0.76)

The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Moleculin Short Term Debt vs Capital Stock Analysis

Short Term Debt vs Capital Stock

Short Term Debt vs Capital Stock Correlation Analysis

Correlation Coefficient

Short Term Debt

Capital Stock

Moleculin Biotech fundamental ratios Correlations

Moleculin Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Moleculin Biotech fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Moleculin Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Total Stockholder Equity

Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.98	Total Assets
Capital Surpluse	- 0.97	Retained Earnings Total Equity